Known active bacterial, viral, fungal, mycobacterial, or other infection
Ongoing treatment for systemic bacterial, fungal, or viral infection at Screening
Presence of fungal, bacterial, viral, or other infection requiring oral or IV antimicrobials for management within 7 days of first dose AMG 757
Symptomatic/active bacterial, or fungal, or any other opportunistic infection
Uncontrolled bacterial, viral or fungal infection in the 6 weeks before enrollment.
Known uncontrolled fungal, bacterial, and/or viral infection ?Grade 2.
Active bacterial, fungal or viral infection
Systemic fungal, bacterial, viral or other infection that is not controlled.
Current active, uncontrolled bacterial, viral, or fungal infection
Active bacterial or viral infection
Evidence of an ongoing systemic bacterial, fungal, or viral infection.
Participants with active viral, bacterial or fungal infection requiring concurrent antiviral or antibiotics
Active >= grade 3 viral, bacterial, or fungal infection within 2 weeks prior to day 1 of protocol therapy
Active bacterial, fungal, or viral infection
PROCUREMENT EXCLUSION: Active bacterial fungal or viral infection
TREATMENT EXCLUSION: Active bacterial, viral or fungal infection
Systemic fungal, bacterial, viral or other infection that is not controlled
Active invasive fungal infection requiring treatment with anti-fungal medication
Active uncontrolled acute fungal, bacterial, or other infection that is unresponsive to therapy at time of study drug dosing
Have an active fungal, bacterial, and/or known viral infection
Uncontrolled viral or bacterial infection at the time of study enrollment
AUTOLOGOUS APHERESIS: Severe intercurrent bacterial, viral or fungal infection
TREATMENT WITH SJCAR19: Severe, uncontrolled bacterial, viral or fungal infection
Subjects with uncontrolled systemic fungal, bacterial, viral or other infection despite appropriate antibiotics or other treatment at the time of leukapheresis or during day 0 (within 24 hrs of CAR T infusion)
Having any uncontrolled illness including ongoing or active bacterial, viral or fungal infection
Presence of fungal, bacterial, viral, or other infection requiring IV antimicrobials for management within 7 days of enrollment. Note: Simple UTI and uncomplicated bacterial pharyngitis are permitted if responding to active treatment and after consultation with sponsor.
Any active grade 3 or higher (per NCI CTCAE version 4.03) viral, bacterial, or fungal infection within 2 weeks of the first dose of the study drug. Routine antimicrobial prophylaxis is permitted.
Currently receiving systemic antimicrobial treatment for active infection (viral, bacterial, or fungal) at the time of first dose of enfortumab vedotin. Routine antimicrobial prophylaxis is permitted.
Presence of fungal, bacterial, viral, or other infection that is uncontrolled or requiring IV antimicrobials for management.
Active bacterial, fungal or viral infection.
Subjects with uncontrolled systemic fungal, bacterial, viral or other infection despite appropriate antibiotics or other treatment at the time of leukapheresis
Uncontrolled bacterial, viral or fungal infection in the 6 week before enrollment
Known uncontrolled fungal, bacterial, and/or viral infection ?Grade 2
Active viral, bacterial, or fungal infection progressing on current treatment
Active bacterial, fungal or viral infection not controlled by adequate treatment, at enrollment.
Active bacterial, fungal or viral infection not controlled by adequate treatment, at enrollment
Patients with uncontrolled systemic fungal, bacterial, viral or other infection are ineligible
Presence of fungal, bacterial, viral, or other infection requiring IV antimicrobials for management. Note: Simple urinary tract infection (UTI) and uncomplicated bacterial pharyngitis are permitted if responding to active treatment.
Ongoing or active infection (bacterial, fungal, or viral) of National Cancer Institute (NCI)-CTCAE version 4.03 grade > 2
Presence of fungal, bacterial, viral, or other infection that is uncontrolled or requiring intravenous antimicrobials for management.
Uncontrolled systemic fungal, bacterial, viral, or other infection
Active systemic fungal, bacterial, viral, or other infection, unless disease is under treatment with anti-microbials and/or controlled or stable; patients with fever thought to be likely secondary to leukemia are eligible; known hypersensitivity to any study drug
Documented fungal infection within 3 months of BMT
Active bacterial, fungal or viral infection
Patients with uncontrolled active infection (viral, bacterial, and fungal) are not eligible
Active >= grade 3 (per NCI CTCAE v4) viral, bacterial, or fungal infection within 2 weeks prior to initiation of study treatment
Does not have current uncontrolled bacterial, fungal, or viral infection
Uncontrolled active systemic infection (viral, bacterial, and fungal)
Acute bacterial, viral, or fungal infection requiring treatment at the time of registration
Active uncontrolled systemic fungal, bacterial or viral infection
uncontrolled infection including evidence of ongoing systemic bacterial, fungal, or viral infection (excluding viral upper respiratory tract infections) at the time of initiation of study treatment;
Uncontrolled active systemic infection (viral, bacterial, and fungal)
Active bacterial, fungal or viral infection including hepatitis B (HBV), hepatitis C (HCV) , requiring treatment with intravenous (IV) antibiotic, IV anti-fungal, or anti-viral; (testing is not required for eligibility)
Uncontrolled viral, fungal, or bacterial infection
REGORAFENIB EXCLUSION CRITERIA: Known active infection (bacterial, fungal, viral); viral infection includes known HIV positivity, or current chronic or active hepatitis B or C infection requiring treatment with antiviral therapy
ENTRECTINIB EXCLUSION CRITERIA: Known active infection (bacterial, fungal, viral including HIV positivity)
Active systemic fungal, bacterial, viral or other infection, unless disease is under treatment with antimicrobials and considered controlled in the opinion of the investigator
Active serious systemic disease, including active bacterial or fungal infection
Active viral, fungal, bacterial or other infection
Active fungal infection or bacterial sepsis
Patients should not have any uncontrolled illness including ongoing or active bacterial, viral or fungal infection
Patients must not have an uncontrolled bacterial, fungal or viral infection, defined as progressive symptoms despite therapy, at the time of the CD8+ memory T-cell infusion; asymptomatic viremia is allowed
Patients with uncontrolled active infection (viral, bacterial, and fungal) are not eligible
Patients with documented active bacterial, viral or fungal infection, untreated systematic peptic ulcer disease, uncontrolled diabetes mellitus or serious concurrent medical disease that could limit survival to less than 3 months
PART 2: Uncontrolled viral or bacterial infection at the time of study enrollment
An uncontrolled bacterial, viral, or fungal infection or an active duodenal ulcer, until these conditions are corrected or controlled.
Does not have current uncontrolled bacterial, fungal, or viral infection
Known mixed invasive mold fungal infection including Zygomycetes, and/or a known invasive Aspergillus fungal infection in which either study drug may not be considered active.
Active uncontrolled bacterial, viral, or fungal infection until these conditions are corrected or controlled
Uncontrolled viral, bacterial or fungal infection
Uncontrolled bacterial, mycobacterial, or fungal infection
Active ongoing viral, bacterial, or fungal infection
Active viral, bacterial or fungal infection unless adequately treated; for fungal infection, patient should have completed full course of antifungal therapy with resolution of infection
Active viral, bacterial or fungal infection
Uncontrolled viral or bacterial infection at the time of study enrollment
Uncontrolled viral or bacterial infection at the time of study enrollment
Active fungal, bacterial, and/or viral infection.
Other serious uncontrolled conditions such as fungal, bacterial or viral infection; HIV, Hepatitis B or C, bleeding disorders, interstitial lung disease,
Patients with known NCI CTCAE Grade 3 or higher (requiring IV antibiotics) active systemic or cutaneous viral, bacterial, or fungal infection.
Evidence of ongoing systemic bacterial, fungal, or viral infection at the time of enrollment
Active systemic fungal, bacterial, and/or viral infection.
Any active viral, bacterial, or systemic fungal infection within 4 weeks prior study entry
216 Presence of fungal, bacterial, viral, or other infection requiring IV antimicrobials for management within 7 days of first dose AMG 562. NOTE: Simple UTI and uncomplicated bacterial pharyngitis are permitted after consultation with sponsor and if responding to active treatment.
Uncontrolled systemic fungal, bacterial, viral or other infection despite appropriate antibiotics or other treatment at the time of leukapheresis or lisocabtagene maraleucel administration
Acute viral, bacterial, or fungal infection, which requires specific therapy. Acute therapy must have been completed at least 7 days prior to study treatment.
Uncontrolled active systemic fungal, bacterial, viral, or other infection or requirement for intravenous (IV) antibiotics
Presence of fungal, bacterial, viral, or other infection requiring IV antimicrobials for management\r\n* Note: Simple urinary tract infection (UTI) and uncomplicated bacterial pharyngitis are permitted if responding to active treatment
Uncontrolled viral or bacterial infection at the time of study enrollment
Participant had a serious infection within 2 weeks prior to randomization, including any Grade 3 or higher viral, bacterial, or fungal infection.
Evidence of active viral, bacterial, or systemic fungal infection.
Patients with a systemic fungal, bacterial, viral, or other infection not controlled
Active bacterial, viral, or fungal infection
Serious concomitant disorder, including active bacterial, fungal, or viral infection, incompatible with the study (at the discretion of the principal investigator)
Any active grade 3 or higher (per NCI CTCAE version 4.03) viral, bacterial, or fungal infection within 2 weeks of the first dose of the study drug. Routine antimicrobial prophylaxis is permitted.
Has an invasive fungal infection.
active bacterial, fungal infection, or detectable viral infection
Uncontrolled acute life threatening bacterial, viral or fungal infection (e.g. blood culture positive ? 72 hours prior to infusion)
Uncontrolled acute life threatening bacterial, viral or fungal infection
Evidence of ongoing systemic bacterial, fungal, or viral infection at the time of start of study drug
Uncontrolled systemic fungal, bacterial, or viral infection
Have active bacterial, fungal, and/or known viral infection.
Active bacterial infection
Active bacterial, viral, fungal, or other infection
Serious systemic fungal, bacterial, viral, or other infection that is not controlled or requires intravenous antibiotics
Progressive or persistent viral or bacterial infection
Active bacterial infection
Patients with a history of active systemic fungal infection.
Presence of fungal, bacterial, viral, or other infection that is uncontrolled or requiring IV antimicrobials for management.
Patients with uncontrolled active infection (viral, bacterial, and fungal) are not eligible
Any history of current or within the past 48 hours of acute or chronic bacterial, fungal or viral infectious disease
Have active bacterial or fungal infection, or detectable viral infection
Have an active infection of any kind (fungal, viral, or bacterial)
Systemic fungal, bacterial, viral, or other infection that is not controlled
Uncontrolled bacterial, viral or fungal infection
Active viral, bacterial or fungal infection
Patients with a systemic fungal, bacterial, viral, or other infection not controlled despite appropriate antibiotics or other treatment; uncontrolled systemic infections require infectious disease consultation for verification
Uncontrolled viral or bacterial infection at the time of study enrollment
Uncontrolled viral, bacteria or fungal infection at time of study enrollment
Subjects with acute infection: any acute viral, bacterial, or fungal infection which requires specific therapy; acute therapy must have been completed more than 14 days prior to study treatment
Active viral, bacterial or fungal infection
Active bacterial or viral infection
Active fungal, bacterial, and/or viral infection
Active viral, bacterial or fungal infection
Uncontrolled systemic bacterial, fungal or viral infection
The participant has active bacterial infection, fungal infection, or detectable viral infection or viral load.
Patients with other conditions not related to leukemic relapse (e.g. veno-occlusive disease or uncontrolled bacterial, viral or invasive fungal infection) which are also life-threatening and which would preclude evaluation of the effects of a T cell infusion
Evidence of ongoing systemic bacterial, fungal, or viral infection at the time of enrollment
Systemic fungal, bacterial, viral, or other infection that is not controlled, at the time of screening
Evidence of ongoing systemic bacterial, fungal, or viral infection at the time of randomization
Fungal or viral infection requiring additional therapy
Evidence of ongoing systemic bacterial, fungal, or viral infection at the time of enrollment
Have an active, known fungal, bacterial, and/or known viral infection.
Current uncontrolled bacterial, viral or fungal infection.
Have an active infection of any kind (fungal, viral, or bacterial)
Evidence of ongoing systemic bacterial, fungal, or viral infection at the time of enrollment
Active bacterial, fungal or viral infection.
Have an active, known fungal, bacterial, and/or known viral infection.
Presence of fungal, bacterial, viral, or other infection that is uncontrolled or requiring IV antimicrobials for management. Simple UTI and uncomplicated bacterial pharyngitis are permitted if responding to active treatment
Active symptomatic fungal, bacterial and/or viral infection including evidence of infection with HIV, HTL, positive serology for HCV or HBV (acute or chronic infection based on CDC guidelines)
Have a known active fungal, bacterial, and/or known viral infection. Hepatocellular cancer participants with chronic viral (B or C) hepatitis are eligible if they retain adequate liver function.
Viral, bacterial, or fungal infection within 2 weeks prior to the first dose of treatment.
Evidence of uncontrolled systemic bacterial, fungal, or viral infection at the start of study drug
Active viral, bacterial or fungal infection requiring intravenous treatment with antimicrobial therapy starting less than four weeks prior to first dose.
Active bacterial, viral, or fungal infection
Does not have current uncontrolled bacterial, fungal, or viral infection
Patient has a current uncontrolled bacterial, fungal, or viral infection per the judgment of the principal investigator (PI)
Active systemic fungal, bacterial, viral, or other infection, unless under treatment with anti-microbials and controlled/stable, as defined as being afebrile and hemodynamically stable for 24-48 hours
Active uncontrolled bacteria, fungal or viral infection
Does not have current uncontrolled bacterial, fungal, or viral infection per the judgment of the principal investigator (PI)
Active bacterial infection
Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection
Patients with uncontrolled active infection (viral, bacterial, and fungal) are not eligible
Evidence of any viral, bacterial, or fungal infection involving the lung and not responding to appropriate treatment
Active infection (symptomatic bacterial and fungal infection â€“ newly diagnosed and/or requiring treatment)
Patients with a documented active infection prior to starting their preparative regimen; this includes grade 3 or higher viral, bacterial, or fungal infection
Patients with a documented active infection prior to starting their preparative regimen; this includes grade 3 or higher viral, bacterial, or fungal infection
Patients with a documented active infection prior to starting their preparative regimen; this includes grade 3 or higher viral, bacterial, or fungal infection
Uncontrolled viral, bacterial, fungal or protozoal infection at the time of study enrollment
Uncontrolled bacterial, viral infection or invasive fungal infection
Active bacterial, viral, fungal infection not controlled with appropriate antimicrobial therapy
Subjects who are being treated for fungal, viral, or bacterial pneumonia
Uncontrolled bacterial, viral or fungal infection at the time of leukapheresis, lymphodepleting chemotherapy or JCAR017 infusion
Respiratory illness of a bacterial or viral etiology within 30 days of MRI
Presence of fungal, bacterial, viral, or other infection requiring IV antimicrobials for management.
Invasive bacterial infection
Active serious systemic disease, including active bacterial or fungal infection within 2 weeks before study entry
